AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17239474
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (IG) 10 units daily (doses increased until fasting glucose <120mg/dl)
Trial: 14963058
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein diet (at least 20 g) and isoflavones (at least 80 mg) for 5 weeks
Trial: 11758227
Drug: Lupus anticoagulant
RxNorm normalized name: Lupus anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lupus anticoagulant (LA) IgG from SLE patients
Trial: 9412880
Drug: Aprotinin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (2 x 10(6) kallikrein inhibitor units in CPB prime)
Trial: 3085551
Drug: nalbuphine (0.21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nalbuphine (0.21 mg/kg, intravenous)
Trial: 3085551
Drug: naloxone (0.014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naloxone (0.014 mg/kg, intravenous)
Trial: 31246234
Drug: Abiraterone acetate,
RxNorm normalized name: abiraterone acetate, submicronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone acetate, 1000 mg, once daily with prednisone, 5 mg, twice daily
Trial: 31246234
Drug: Abiraterone acetate,
RxNorm normalized name: abiraterone acetate, submicronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone acetate, 1000 mg, once daily with prednisone, 5 mg, once daily
Trial: 31246234
Drug: Abiraterone acetate,
RxNorm normalized name: abiraterone acetate, submicronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone acetate, 1000 mg, once daily with prednisone, 2.5 mg, twice daily
Trial: 31246234
Drug: Abiraterone acetate,
RxNorm normalized name: abiraterone acetate, submicronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone acetate, 1000 mg, once daily with dexamethasone, 0.5 mg, once daily
Trial: 26894653
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg febuxostat twice daily
Trial: 26894653
Drug: 40/80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40/80 mg febuxostat once daily
Trial: 15640324
Drug: Oral L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral L-arginine supplementation (200 mg x kg(‐1) body weight, t.i.d. for 6 weeks)
Trial: 15640324
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral L-arginine (200 mg x kg(‐1) body weight)
Trial: 1369702
Drug: Nicardipine 30
RxNorm normalized name: niCARdipine 30 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 30 mg t.i.d. for 2 weeks
Trial: 36817
Drug: Cimetidine, 300
RxNorm normalized name: Cimetidine, 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine, 300 mg IV, 2 hr before induction of anesthesia
Trial: 36817
Drug: Glycopyrrolate, 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate, 0.3 mg IM, 1 hr before induction of anesthesia
Trial: 16540851
Drug: Caffeine 10
RxNorm normalized name: caffeine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 10 mg x kg(‐1) body weight
Trial: 16540851
Drug: Caffeine 5
RxNorm normalized name: caffeine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 5 mg x kg(‐1) body weight
Trial: 11680666
Drug: Losartan +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan + Diuretic (L+D)
Trial: 11680666
Drug: Calcium Channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium Channel Blocker + Diuretic (N+D)
Trial: 9270666
Drug: Propionyl-L-carnitine (PLC)
RxNorm normalized name: glycine propionyl-L-carnitine
DrugBank: Levocarnitine propionate (DB15980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propionyl-L-carnitine (PLC) (1.5 g i.v. followed by infusion of 1 mg/kg/min for 30 min, n = 10)
Trial: 9270666
Drug: L-carnitine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (1 g i.v. followed by infusion of 0.65 mg/kg/min for 30 min, n = 6)
Trial: 8197037
Drug: Ceftizoxime 1
RxNorm normalized name: ceftizoxime 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftizoxime 1 g plus metronidazole 500 mg intravenously every 12 hours
Trial: 8197037
Drug: Cefoxitin 2
RxNorm normalized name: cefoxitin 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin 2 g intravenously every 6 hours
Trial: 8197037
Drug: Ampicillin-sulbactam 3
RxNorm normalized name: ampicillin / sulbactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin-sulbactam 3 g every 6 hours
Trial: 30430875
Drug: Combination topical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination topical gel of nifedipine (NIF), lidocaine hydrochloride (LDH), and betamethasone valerate (BMV)
Trial: 30430875
Drug: Market products
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Market products (single drug treatments)
Trial: 27435332
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg intravenous tranexamic acid (TXA)
Trial: 22538054
Drug: Budesonide (3mg)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide (3mg) infused locally in the proximal jejunum after administering ketoconazole (doses ranging from 1-128 mg, with an oral dose of 200mg given 12h earlier)
Trial: 22538054
Drug: Ketoconazole (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (up to 16 mg)
Trial: 22538054
Drug: Ketoconazole (64
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (64 mg and above)
Trial: 22538054
Drug: Ketoconazole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (1 mg in mucosa and 50 mg in liver)
Trial: 22538054
Drug: Budesonide (0.2mg)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide (0.2mg) administered intravenously
Trial: 19640853
Drug: Onercept 50
RxNorm normalized name: Onercept
DrugBank: Onercept (DB06495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onercept 50 mg and 100 mg
Trial: 18545216
Drug: Intranasal heating
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal heating and humidification in elderly subjects
Trial: 9329640
Drug: Blood cells
RxNorm normalized name: Red blood cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood cells of patients subjected to radioiodine therapy
Trial: 24955450
Drug: Esomeprazole and
RxNorm normalized name: Esomeprazole and naproxen only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole and flupentixol/melitracen (combination therapy)
Trial: 24955450
Drug: Esomeprazole only
RxNorm normalized name: Esomeprazole only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole only (monotherapy)
Trial: 23372114
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with darunavir/ritonavir + 2 NRTIs
Trial: 14520123
Drug: Mirtazapine 30
RxNorm normalized name: mirtazapine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine 30 mg/d
Trial: 10926339
Drug: 800 microg
RxNorm normalized name: Fentanyl 800 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 microg inhaled budesonide per day
Trial: 10926339
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg inhaled budesonide per day
Trial: 4017661
Drug: Albumin group
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin group (ALB) received 80 g albumin on the day of operation and 20 g albumin for the following three days.
Trial: 24331842
Drug: Milrinone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (50 μg/kg/min loading dose followed by 0.6 μg/kg/min continuous infusion)
Trial: 22251615
Drug: Tibolone, 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone, 2.5 mg daily
Trial: 12595513
Drug: Steroid withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid withdrawal (n = 5)
Trial: 12595513
Drug: CsA discontinuation/reduction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA discontinuation/reduction (n = 13)
Trial: 12595513
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (n = 12)
Trial: 12595513
Drug: Lowering CsA
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowering CsA to low target trough (30 to 70 ng/ml)
Trial: 11039423
Drug: Membrane differential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Membrane differential filtration treatment, administered five times over a period of 21 weeks.
Trial: 11039423
Drug: Membrane differential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Membrane differential filtration treatment.
Trial: 9020990
Drug: Pirlindole (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirlindole (300 mg/day)
Trial: 2864741
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g sulphasalazine daily
Trial: 2864741
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg penicillamine daily
Trial: 25887355
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (HbA1c goal < 6%)
Trial: 25887355
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (HbA1c goal 7.0% to 7.9%)
Trial: 21438849
Drug: Tipranavir/ritonavir (TPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tipranavir/ritonavir (TPV/r) 500 mg/200 mg
Trial: 19568175
Drug: Nevirapine (NVP)
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nevirapine (NVP) administration to women who tested positive for HIV
Trial: 19568175
Drug: Inert (calcium)
RxNorm normalized name: inert ingredients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert (calcium) tablet provided to women who tested negative for HIV
Trial: 1585511
Drug: CisCA chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CisCA chemotherapy
Trial: 27704507
Drug: 10 IU
RxNorm normalized name: Thyrotropin 10 IU Injection Powder for Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 IU bolus of Oxytocin + 25 IU IVD in 500 ml of serum over 3 hours
Trial: 27704507
Drug: 5 IU
RxNorm normalized name: Vitamin E 15 IU/0.3 ML Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 IU IVD of Oxytocin + 25 IU in 500 ml serum over 3 hours
Trial: 24667132
Drug: Se-enriched rice
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Se-enriched rice (80 g daily)
Trial: 24667132
Drug: Regular rice
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular rice (80 g daily)
Trial: 22521214
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) 100/325 mg for 7 days
Trial: 20400201
Drug: Gefitinib 250mg
RxNorm normalized name: GEFITINIB 250MG TAB
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gefitinib 250mg daily
Trial: 15876903
Drug: H. perforatum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. perforatum (900-1500 mg/d)
Trial: 15876903
Drug: Sertraline (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50-100 mg/d)
Trial: 12830007
Drug: Octreotide infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide infusion (50 microg/h)
Trial: 11291022
Drug: Treatment approaches
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment approaches to memory loss, typically using Alzheimer's dementia as the template.
Trial: 8676532
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (TPN) continuously throughout the postoperative period
Trial: 8676532
Drug: Saline as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline as postoperative fluid therapy
Trial: 31026086
Drug: Epidural oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural oxycodone 0.1 mg kg‐1 and intravenous saline (EPI-group n = 31)
Trial: 31026086
Drug: Intravenous oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous oxycodone 0.1 mg kg‐1 and epidural saline (IV-group n = 29)
Trial: 27111084
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with memantine
Trial: 20978525
Drug: Betaine supplementation
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betaine supplementation (4 g/day)
Trial: 20978525
Drug: Placebo (mineral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (mineral water 500 ml/day without betaine)
Trial: 20158691
Drug: Ibandronate 2
RxNorm normalized name: ibandronate 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 2 mg every 3 months intravenously for 1 year, along with calcium (1 g/day) and vitamin D3 (800-1000 IE/day)
Trial: 20158691
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving calcium (1 g/day) and vitamin D3 (800-1000 IE/day)
Trial: 8600589
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated varicella vaccine (Oka strain) with a mean virus titre of 10(4,5) PFUs per dose
Trial: 8600589
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated varicella vaccine (Oka strain) with a mean virus titre of 10(3,1) PFUs per dose
Trial: 8600589
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated varicella vaccine (Oka strain) with a mean virus titre of 10(3,9) PFUs per dose
Trial: 8600589
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated varicella vaccine (Oka strain) with a mean virus titre of 10(2,7) PFUs per dose
Trial: 8600589
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated varicella vaccine (Oka strain)
Trial: 361345
Drug: Loxapine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxapine (average maximum daily dose: 60.0 mg)
Trial: 361345
Drug: Perphenazine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perphenazine (average daily dosage: 36.8 mg)
Trial: 361345
Drug: Loxapine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxapine (average daily dosage: 81.1 mg)
Trial: 361345
Drug: Perphenazine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perphenazine (average daily dosage: 90.1 mg)
Trial: 27995369
Drug: Oral analgesics
RxNorm normalized name: ANALGESIC CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral analgesics (paracetamol, ibuprofen, or a combination)
Trial: 11206598
Drug: Once-weekly fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly fluoxetine
Trial: 11206598
Drug: Once-daily fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily fluoxetine
Trial: 3705820
Drug: Tranquilizers, antidepressants,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tranquilizers, antidepressants, neuroleptics, nootropic drugs, and rational psychotherapy
Trial: 27367877
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (n=143) provided by primary care physician including periodic contacts, referrals to specialists, and prescription of medication.
Trial: 18541128
Drug: Test formulation:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation: ibuprofen (400 mg capsule)
Trial: 12135217
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion hysterosonography
Trial: 10374704
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus aspirin (single therapy)
Trial: 10374704
Drug: Complete therapy
RxNorm normalized name: Monistat 7 Complete Therapy Combination Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete therapy (lymphocyte immunizations, heparin, and aspirin)
Trial: 7487614
Drug: Systemic antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotics (ceftazidime and amikacin)
Trial: 2299370
Drug: Low-dose cytarabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytarabine (LD ARA‐C) 20 mg/m2 for 21 days
Trial: 2299370
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy (rubidazone 100 mg/m2 for 4 days, ARA‐C 200 mg/m2 for 7 days)
Trial: 29159870
Drug: Predictive low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predictive low glucose suspension (PLGS) alone
Trial: 26619790
Drug: Yogurt with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yogurt with 6 g inulin (YI)
Trial: 11836166
Drug: Slow response
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow response to therapy (assessed by percentage of blast cells higher than 10% in bone marrow study on day 14)
Trial: 11836166
Drug: Slow response
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow response to therapy (assessed by presence of blast cells in peripheral blood on day 8)
Trial: 1986564
Drug: Isocaloric 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric 0.8 g/kg protein diet
Trial: 29878445
Drug: Supervised resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised resistance training twice-a-week for 9 months
Trial: 16000281
Drug: 18F‐FCWAY (5‐HT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F‐FCWAY (5‐HT 1A receptor antagonist)
Trial: 10621951
Drug: Sumatriptan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (100 mg orally)
Trial: 10621951
Drug: Subsequent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent treatment with serotonin specific reuptake inhibitors (SSRIs)
Trial: 7860745
Drug: 600 mg/d
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/d cholesterol with high saturated fat
Trial: 7860745
Drug: 600 mg/d
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/d cholesterol with increased polyunsaturated fat
Trial: 7860745
Drug: 200 mg/d
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/d cholesterol with high saturated fat
Trial: 7860745
Drug: 200 mg/d
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/d cholesterol with low saturated fat
Trial: 7860745
Drug: 600 mg/d
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/d cholesterol with low saturated fat
Trial: 1955161
Drug: Adrenaline injection
RxNorm normalized name: epinephrine Injection [Adrenalin]
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adrenaline injection + Nd:YAG laser photocoagulation
Trial: 6135908
Drug: ICI 118630
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 118630 (100 micrograms daily)
Trial: 6135908
Drug: ICI 118630
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 118630 (250 micrograms daily)
Trial: 24393134
Drug: UMEC 125
RxNorm normalized name: Umecta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UMEC 125 μg QD
Trial: 24393134
Drug: Other UMEC
RxNorm normalized name: Umecta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other UMEC doses (15.6, 31.25, 62.5 μg)
Trial: 21978210
Drug: Daily aphasia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily aphasia therapy
Trial: 21978210
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care therapy
Trial: 17457705
Drug: Tramadol as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol as PCA with an infusion of 0.3 mg/kg following a loading dose of 1.5 mg/kg administered 1 hour before the end of the surgery
Trial: 17457705
Drug: Ondansetron 0.1
RxNorm normalized name: ONDANSETRON 0.16MG/ML D5W INJ BAG 50ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.1 mg/kg following induction of anesthesia
Trial: 17457705
Drug: Morphine as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine as PCA with an infusion following a loading dose of 0.15 mg/kg administered 30 minutes before the end of surgery
Trial: 17720075
Drug: Ophthalmic review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic review 2 hours after surgery and 2 weeks postoperatively (Group 1)
Trial: 17720075
Drug: No ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ophthalmic review before the 2-week postoperative visit (Group 2)